Journal of Hematology and Oncology Research

The Open Access Pub has the reputation for quick reviewing and publishing original research articles. The editorial boards of our journals have many dedicated and reputed scientists as editorial members. Their support helps many researchers from all countries to enhance their research between scientists of various communities. This platform plays a crucial role in promoting science networks and exchanges.

Journal of Hematology and Oncology Research- Oncology

USA

Director, Legorreta Cancer Center at Brown University

Send an Email

Wafik S. El-Deiry

Address:

University Professor of Medical Science, Professor of Pathology and Laboratory Medicine

Research Interests:

Molecular Oncology, Cancer Molecular Targets and Therapeutics Section, Pharmacology and Genetics, Hematology, Oncology

Biography:

Wafik El-Deiry, MD, PhD, FACP is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School, Director of the Cancer Center at Brown University, and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals. He is an American Cancer Society Research Professor, Professor of Pathology and Laboratory Medicine, Professor of Medical Science, and Mencoff Family University Professor at Brown University.

Publications:

  • Hsu, A., Huntington, K.E., De Souza, A., Zhou, L., Olszewski, A.J., Makwana, N.P., Treaba, D.O., Cavalcante, L., Giles, F.J., Safran, H., El-Deiry, W.S., and Carneiro, B.A. Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3b) inhibitor, in refractory adult T-Cell leukemia/lymphoma. Cancer Biol Ther. 2022 Dec 31;23(1):417-423. doi: 10.1080/15384047.2022.2088984.
  • Darabi, S., Braxton, D.R., Xiu, J., Carneiro, B.A., Swenson, J., Antonarakis, E.S., Liu, S.V., McKay, R.R., Spetzler, D., El-Deiry, W.S., and Demeure, M.J. BRCA1/2 reversion mutations in patients treated with Poly ADP-Ribose Polymerase (PARP) inhibitors or platinum agents. Medicina (Kaunas). 2022 Dec 10;58(12):1818. doi: 10.3390/medicina58121818.
  • Gonzalez, Z., Carlsen, L., and El-Deiry, W.S. Temozolomide combined with ipilimumab plus nivolumab enhances T cell killing of MGMT-expressing, MSS colorectal cancer cells. Am J Cancer Res. 2023 Jan 15;13(1):216-226. eCollection 2023.